HM15912

DRUG2 trials

Sponsors

Hanmi Pharmaceutical Company Limited

Conditions

PharmacologyRenal Impairment

Phase 1

Single Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15912(Sonefpeglutide) in Healthy Korean Subjects

CompletedNCT04076293

Hanmi Pharmaceutical Company LimitedPharmacology

Start: 2019-10-08End: 2021-05-03Updated: 2025-02-10

Phase 1 Study of PK and Safety of HM15912 (Sonefpeglutide) in Subjects With Normal and Severe Kidney Function

CompletedNCT05711381

Hanmi Pharmaceutical Company LimitedRenal Impairment

Start: 2022-12-02End: 2023-08-15Updated: 2025-04-04